Allegra, Zyrtec Will Not Follow Claritin OTC In Near Future, Execs State
This article was originally published in The Tan Sheet
Executive Summary
Aventis and Pfizer have no plans to switch their low- and non-sedating antihistamines OTC in the wake of Schering-Plough's decision to pursue FDA approval of nonprescription Claritin, company execs said at the SG Cowen healthcare conference in Boston March 13
You may also be interested in...
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan
Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.